Holen Sie sich die Stockscreener-App
21.60
2.13%
-0.47
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Rafferty Asset Management LLC - MarketBeat
Ultragenyx EVP Pinion sells $228k in shares - Investing.com
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Navan, Inc. Notice of April 24, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Ultragenyx Pharmaceutical (NASDAQ:RARE) Insider Sells $228,661.20 in Stock - MarketBeat
Howard Horn Sells 1,635 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells $185,478.00 in Stock - MarketBeat
Theodore Alan Huizenga Sells 1,632 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Eric Crombez Sells 7,029 Shares - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells 10,539 Shares - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $190,884.30 in Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) CEO Sells 54,404 Shares - MarketBeat
Ultragenyx (RARE) EVP Harris receives stock award, sells shares for taxes - Stock Titan
Ultragenyx (RARE) legal chief receives stock award, sells shares for taxes - Stock Titan
Ultragenyx (RARE) CAO disposes shares in RSU tax-related transactions - Stock Titan
Ultragenyx (RARE) CFO nets stock award and sells 10,044 shares - Stock Titan
Ultragenyx (RARE) CMO reports stock award and sale of common shares - Stock Titan
Ultragenyx (RARE) executive reports stock grant and tax share surrender - Stock Titan
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - ChartMill
Shareholders that lost money on Ultragenyx Pharmaceutical Inc.(RARE) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
Howard Horn sells RARE shares (NASDAQ: RARE) in Form 144 disclosure - Stock Titan
Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx ... - Bluefield Daily Telegraph
Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx Pharmaceutical - marketscreener.com
NASDAQ: RARE Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ - marketscreener.com
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - PR Newswire
Ultragenyx Pharmaceutical Inc. Investors with Substantial - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsRARE - marketscreener.com
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - marketscreener.com
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire
Vanguard Group Inc. Sells 80,694 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 – Company AnnouncementFT.com - Financial Times
69,248 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Thornburg Investment Management Inc. - MarketBeat
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Volatility - Yahoo Finance
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRARE - The Malaysian Reserve
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - marketscreener.com
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRARE - TMX Newsfile
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - marketscreener.com
LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION - PR Newswire
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline - Sahm
Ultragenyx Pharmaceutical (RARE) Is Up 12.7% After FDA Grants Priority Review To DTX401 Gene TherapyHas The Bull Case Changed? - simplywall.st
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring a Remarkable 151% Potential Upside - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
RARE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - TMX Newsfile
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE - ChartMill
Lawsuit Alert: Investors who lost money with Ultragenyx - openPR.com
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory - Finviz
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Ultragenyx Pharmaceutical Inc.(RARE) Shareholders (2026-02-24) - Seeking Alpha
Ultragenyx Pharmaceutical Faces Investor Lawsuit Following Study Failures and Stock Decline - TipRanks
Holzer & Holzer, LLC Reminds RARE Investors of the April 6, - GlobeNewswire
FDA Grants Priority Review for Ultragenyx's (RARE) Gene Therapy Application - GuruFocus
Three health conferences where Ultragenyx will field investor questions - Stock Titan
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit - NewMediaWire
ROSEN, A RANKED AND LEADING FIRM, Encourages Ultragenyx - GlobeNewswire
LEVI & KORSINSKY, LLP: PHASE III CLINICAL TRIAL DESIGN AND - GlobeNewswire
UX111 gene therapy shows long-term benefit in Sanfilippo type A: Trial data - Sanfilippo Syndrome News
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
0.14%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):